Phase 4 Uveitis Trial, Completed NCT03133767 Sponsor: Nicholas M Mohr Condition: Uveitis
Back to Uveitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 157 people who visited an emergency department — 79 received a fluid drip called Lactated Ringer's Solution and 78 received Normal Saline Solution (a standard salt-water drip). The trial was measuring how well patients felt they had recovered after receiving one of these two fluids, using a questionnaire called the Quality of Recovery-40 (QoR-40). This is a self-reported survey with 40 questions where patients rate how they are feeling across a range of areas; scores run from 40 (poorest recovery) to 200 (best recovery). Not everyone completed the study — 41 people in the Lactated Ringer's group and 53 in the Normal Saline group finished. The reported data shows that 24 hours after treatment, the average QoR-40 score for the Lactated Ringer's group was 166.8 out of 200, and for the Normal Saline group it was 164.4 out of 200. At an earlier time point — shortly after the fluid was given — the reported average scores were 152.6 for the Lactated Ringer's group and 141.6 for the Normal Saline group. These numbers reflect how patients rated their own recovery at those two points in time. The reported data also shows some follow-up information collected seven days later via text message. In the Lactated Ringer's group, 14 participants reported filling a prescription from the emergency department, 5 reported returning to the emergency department for the same problem, and 9 reported seeing another health provider for the same complaint. In the Normal Saline group, those numbers were 19, 7, and 7 respectively. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Phase 4 Uveitis Trial, Completed

NCT03133767
Completed Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are being seen in an emergency department (ER)
  • Your main reason for visiting the ER is nausea, vomiting, diarrhea, stomach pain, dehydration, heat stroke, or heat exhaustion
  • The ER doctor has agreed that you can receive two liters of fluid (through a drip/IV)
  • The ER doctor expects that you will be able to go home after your visit
  • You have seen your regular family doctor or primary care doctor at least once in the last two years
  • You have access to a phone for the two days after you leave the ER

Who may not be able to join:

  • You are currently in prison or jail
  • You are under 18 years old (confirm with trial site)
  • You are known to be pregnant
  • You have yellowing of the skin or eyes (jaundice)
  • You are currently receiving chemotherapy (cancer treatment)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Phase 4
Sponsor
Nicholas M Mohr
Registry
ClinicalTrials.gov
Start date
23 May 2017
Est. completion
1 November 2017

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Quality of Recovery-40 Score at 24 Hours

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov